Evidence map›Paper›PMID 38426787›Full record

Observational studymSphere2024

Reduced control of SARS-CoV-2 infection associates with lower mucosal antibody responses in pregnancy.

Laura A St Clair, Raghda E Eldesouki, Jaiprasath Sachithanandham, Anna Yin, Amary Fall, C Paul Morris, Julie M Norton, Omar Abdullah, Santosh Dhakal, Caelan Barranta and 10 more

Open access · goldAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in mSphere, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.9field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

20 authors at 8 institutions in 2 countries.

Laura A St Clair *W. Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, USA.
Raghda E Eldesouki *Department of Pathology, Division of Medical Microbiology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Jaiprasath Sachithanandham *W. Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, USA.
Anna Yin *W. Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, USA.
Amary FallDepartment of Pathology, Division of Medical Microbiology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
C Paul MorrisDepartment of Pathology, Division of Medical Microbiology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Julie M NortonDepartment of Pathology, Division of Medical Microbiology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Omar AbdullahDepartment of Pathology, Division of Medical Microbiology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Santosh DhakalW. Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, USA.ORCID 0000-0002-4494-8608
Caelan BarrantaW. Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, USA.
Hana GoldingDivision of Viral Products, Center of Biologics Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA.
Susan J Bersoff-MatchaOffice of Women's Health, U.S. Food and Drug Administration, Silver Spring, Maryland, USA.
Catherine Pilgrim-GraysonDivision of Urology, Obstetrics, and Gynecology, Office of Rare Diseases, Pediatrics, Urologic and Reproductive Medicine and Office of New Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA.
Leah BerhaneDivision of Urology, Obstetrics, and Gynecology, Office of Rare Diseases, Pediatrics, Urologic and Reproductive Medicine and Office of New Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA.
Andrea L CoxW. Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, USA.
Irina BurdDepartment of Obstetrics, Gynecology and Reproductive Sciences, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Andrew PekoszW. Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, USA.ORCID 0000-0003-3248-1761
Heba H MostafaDepartment of Pathology, Division of Medical Microbiology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.ORCID 0000-0002-0274-8966
Eili Y Klein *Department of Emergency Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.ORCID 0000-0002-1304-5289
Sabra L Klein *W. Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, USA.ORCID 0000-0002-0730-5224
Johns Hopkins University · USUnited States Food and Drug Administration · USBloomberg (United States) · USCenter for Biologics Evaluation and Research · USNational Institutes of Health · USSuez Canal University · EGUnited Nations · USUniversity of Maryland, Baltimore · US

Funding

Johns Hopkins Center of Excellence in Regulatory Science and Innovation (JH-CERSI)U01FD005942 · FDA · JOHNS HOPKINS UNIVERSITY · PI ALEXANDER, G. CALEB · 2016 to 2025
$15.5M
Virology Resource CoreU54CA260492 · NCI · JOHNS HOPKINS UNIVERSITY · PI KLEIN, SABRA L. · 2020 to 2024
$10.4M
ACL HHS U01CK000589FDA HHS U01 FD005942NCEZID CDC HHS U01 CK000589NCI NIH HHS U54 CA260492
6 · The paper itself

Abstract

Pregnant patients are at greater risk of hospitalization with severe COVID-19 than non-pregnant people. This was a retrospective observational cohort study of remnant clinical specimens from patients who visited acute care hospitals within the Johns Hopkins Health System in the Baltimore, MD-Washington DC, area between October 2020 and May 2022. Participants included confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-infected pregnant people and matched non-pregnant people (the matching criteria included age, race/ethnicity, area deprivation index, insurance status, and vaccination status to ensure matched demographics). The primary dependent measures were clinical COVID-19 outcomes, infectious virus recovery, viral RNA levels, and mucosal anti-spike (S) IgG titers from upper respiratory tract samples. A total of 452 individuals (117 pregnant and 335 non-pregnant) were included in the study, with both vaccinated and unvaccinated individuals represented. Pregnant patients were at increased risk of hospitalization (odds ratio [OR] = 4.2; confidence interval [CI] = 2.0-8.6), intensive care unit admittance (OR = 4.5; CI = 1.2-14.2), and being placed on supplemental oxygen therapy (OR = 3.1; CI = 1.3-6.9). Individuals infected during their third trimester had higher mucosal anti-S IgG titers and lower viral RNA levels (

Indexed as

COVID-19Pregnancy Complications, InfectiousAntibody FormationBreakthrough InfectionsCohort StudiesFemaleHumansImmunoglobulin GPregnancyRetrospective StudiesRNA, ViralSARS-CoV-2Immunoglobulin GRNA, Viralbreakthrough infectionCOVID-19Delta variantgestationOmicron variant

Identifiers

PMID38426787
PMCPMC10964408
OpenAlexW4392357927

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.